TPTX » Topics » New York, NY - June 30, 2005 -

This excerpt taken from the TPTX 8-K filed Jun 30, 2005.
New York, NY – June 30, 2005 – Axonyx Inc. (NASDAQ: AXYX) a U.S.-based biopharmaceutical company, today announced that Marvin S. Hausman, MD, has elected to step down as Chairman on September 14, 2005 but will remain a director of Axonyx. The board of directors unanimously elected Steven B. Ratoff as non-executive chairman to succeed Dr. Hausman.

 

Dr. Hausman founded Axonyx in 1997 and was instrumental in identifying and licensing - the technologies which are the basis of the company’s current focus. Dr. Hausman is Chairman of Oxis International (OXIS: OB), in which the company owns a 34% interest. He is also a Director of Arbios Systems Inc. (ABOS: OB), a liver dialysis company. Dr. Hausman’s scientific/clinical expertise and interests also include cancer immunology, organ transplantation and infectious diseases.

 

The Company has entered into a consulting agreement with Dr. Hausman that will provide it with continued access to Dr. Hausman’s considerable knowledge and experience.

 

Steven B. Ratoff, a seasoned business executive, joined the Axonyx board on May 5, 2005. Mr. Ratoff is currently a private investor and a Venture Partner with Proquest Investments, a biopharmaceutical venture capital firm. He most recently served as Chairman and Interim Chief Executive Officer of Cima Labs, Inc., a public specialty pharmaceutical company, from May 2003 through its sale to Cephalon, Inc. in August 2004. Mr. Ratoff is currently a director of InKine Pharmaceutical Company, Inc. (NASDAQ: INKP).

 

“I remain committed to Axonyx and to the attainment of its clinical goals,” said Dr. Hausman. “I have great confidence in Steven’s track record of success in the biopharmaceutical industry and believe the right team is in place to move our company forward.”

 

Commenting on the transition, Gosse B Bruinsma, MD, President and CEO of Axonyx stated “We are very appreciative of Marvin’s efforts and experience in growing and financing the company since its inception in 1997 and look forward to continuing our

 

 



 

 

relationship. We look forward to working with Steven and benefiting from his leadership as we continue to develop our CNS pipeline.”

 

This excerpt taken from the TPTX 8-K filed May 5, 2005.
New York, NY – May 5, 2005 – Axonyx Inc. (NASDAQ: AXYX), a U.S.-based biopharmaceutical company, today announced the appointment of Steven B. Ratoff to its Board of Directors, effective immediately. Mr. Ratoff replaces Michael A. Griffith, who resigned from the Board on April 29, 2005 in order to fully pursue a new business venture he is leading. Axonyx currently has seven board members, of which five are outside, independent directors.

 

“We appreciate Mike’s contributions to the Company during his tenure with us and wish him the very best in his new venture,” stated Marvin S. Hausman, M.D., Chairman of the Company. “We are also very pleased to welcome Steven Ratoff to our Board. Steven’s extensive background as a chief executive officer of two life sciences companies, as well as the breath and depth of his finance experience, makes him a valuable addition to our Board.”

 

Mr. Ratoff is currently a private investor and a Venture Partner with Proquest Investments, a biopharmaceutical venture capital firm. He most recently served as Chairman and Interim Chief Executive Officer of Cima Labs, Inc., a public specialty pharmaceutical company, from May 2003 through its sale to Cephalon, Inc. in August 2004.

 

He was the President and Chief Executive Officer of MacroMed, Inc., a privately owned drug delivery company, from February 2001 to December 2001, and also as director since 1998.

 

Mr. Ratoff’s experience includes serving as Executive Vice President and Chief Financial Officer of Brown-Forman Corporation, a public diversified manufacturer of consumer products, as well as fifteen years in a variety of senior financial positions with Bristol-Myers Squibb.

 

Mr. Ratoff is currently a director of InKine Pharmaceutical Company, Inc. (NASDAQ: INKP).

 



 

 

 

EXCERPTS ON THIS PAGE:

8-K
Jun 30, 2005
8-K
May 5, 2005

RELATED TOPICS for TPTX:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki